Open AccessPARP-inhibitors in a non‐oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open
Author(s) -
Ettore Capoluongo
Publication year - 2020
Publication title -
biomedicine and pharmacotherapy
Language(s) - English
Resource type - Journals
eISSN - 1950-6007
pISSN - 0753-3322
DOI - 10.1016/j.biopha.2020.110536
Subject(s) - covid-19 , medicine , antithrombotic , thrombosis , chloroquine , intensive care medicine , pharmacology , immunology , virology , disease , outbreak , infectious disease (medical specialty) , malaria
In the last three months, the whole scientific community has shifted its focus to the fight against the COVI-2 infection (COVID-19) trying to use different medications to save the patients' life. In some studies, the results were completely inconclusive, as in the case of chloroquine. However, the recent discovery on benefits deriving from use of such anticoagulants for Covid-19 patients, has increased the success of patients' treatment. Among lots of old and new drugs, PARP-inhibitors were not considered as possible option in the treatment of Covi-2 infection, being the latter able to induce the inflammatory and thrombotic cascades. Since PARP-inhibitors are able to reduce and block mechanisms leading to thrombosis and inflammation, they could be used as antithrombotic medications. Therefore, the present brief report is aimed to open the discussion on the potentials of PARP-inhibitors in non-oncological settings, like Covid-19.